Nasus Pharma is trading 6.66% down in pre-market at $3.58 after announcing that CFO Eyal Rubin will leave for a new opportunity outside the life-science industry.
- The announcement was made August 19, 2026; Rubin will remain through September 18.
- Director of Finance Oren Elmaliach will become interim CFO.
- The decline follows a 5.21% gain on August 19, while healthcare-sector strength does not explain the opposite-direction move.